The role interferon-alpha in malignant melanoma remains to be defined

European Journal of Cancer

Volumn 37, Issue 17, 2001, Pages 2147-2153

  Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Interferon alpha; Melanoma; Randomised trial

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; TAMOXIFEN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; MAINTENANCE THERAPY; MELANOMA; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0034777045     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00272-6     Document Type: Article

References (30)

1. Melanoma
2. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
3. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic melagnant melanoma
4. Interferon-alpha 2a does not improve response or survival when combined with dacarbazide in metastatic malignant melanoma: Results of a multi-institutional Australian randomized trial
5. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
6. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma
7. Phase III trial of dacarbazine versus dacarbazide with interferon alpha2b versus dacarbazide with tamoxifen versus dacarbazide with interferon alpha2b with tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Study
8. Randomized phase II trial of BCDT with or without interferon alpha and interleukin-2 in patients with metastatic melanoma
9. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
10. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study
11. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2B (INF) versus CVD in patients (pts) with metastatic melanoma
12. Interferon-a2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
13. Randomised trial of interferon a-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases
14. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
15. Randomized surgical adjuvant clinical trial or recombinant interferon-alfa-2a in selected patients with malignant melanoma
16. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
17. Pooled analysis of four ECOG-Intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma
18. Results of adjuvant interferon study in WHO melanoma programme
19. Evaluation of efficacy of adjuvant rIFNα 2A in regional node metastases
20. Aim high-adjuvant interferon in melanoma (high risk), a United Kingdom co-ordinating Committee on Cancer Research (IKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alfa-2a in high risk resected malignant melanoma
21. The European Organization for research and Treatment of Cancer Melanoma Group Trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon Alpha-2b
22. Adjuvant interferon alpha in high risk melanoma: The Scottish study
23. Adjuvant interferon a-2a treatment in resected primary stage II cutaneous melanoma
24. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
25. Molecular staging of malignant melanoma: Correlation with clinical outcome
26. Multi-institutional melanoma lymphatic mapping experience: Value of sentinel lymph node status in 612 stage I or stage II melanoma patients
27. The Current Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: Prognosis versus efficacy, toxicity and costs
28. Prospective randomized trials in melanoma: Defining contemporary surgical roles
29. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma
30. Interferon-α as adjuvant therapy for melanoma: A meta-analysis of the randomised trials